Somatic impairment of the CDKN2A gene in melanoma can occur by genetic deletions, inactivated mutations, or promoter hypermethylation and leads to a decrease of the function of p16CDKN2A and/or p14CDKN2A proteins, with consequent loss of cell cycle control. This evidence concerns the gene CDKN2A and melanoma.